Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation

Inflammatory myofibroblastic tumor (IMT), a rare sarcoma, is primarily treated via resection of the mass. However, in cases of recurrence or unresectable tumors, no standard care exists. While crizotinib, an anaplastic lymphoma kinase (ALK) inhibitor, is only approved for non-small-cell lung cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogata, Misato, Hatachi, Yukimasa, Ogata, Takatsugu, Satake, Hironaga, Imai, Yukihiro, Yasui, Hisateru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478978/
https://www.ncbi.nlm.nih.gov/pubmed/30449794
http://dx.doi.org/10.2169/internalmedicine.1640-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478978/
https://www.ncbi.nlm.nih.gov/pubmed/30449794
http://dx.doi.org/10.2169/internalmedicine.1640-18

Ejemplares similares